Department of Medicine, Einstein Institute for Aging Research, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), The Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York, NY, USA.
Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Institute for Neuroimmunology and Inflammation (INI),, Albert Einstein College of Medicine, New York, NY, USA.
Cardiovasc Diabetol. 2022 Feb 14;21(1):23. doi: 10.1186/s12933-022-01460-5.
Restenosis, defined as the re-narrowing of an arterial lumen after revascularization, represents an increasingly important issue in clinical practice. Indeed, as the number of stent placements has risen to an estimate that exceeds 3 million annually worldwide, revascularization procedures have become much more common. Several investigators have demonstrated that vessels in patients with diabetes mellitus have an increased risk restenosis. Here we present a systematic overview of the effects of diabetes on in-stent restenosis. Current classification and updated epidemiology of restenosis are discussed, alongside the main mechanisms underlying the pathophysiology of this event. Then, we summarize the clinical presentation of restenosis, emphasizing the importance of glycemic control in diabetic patients. Indeed, in diabetic patients who underwent revascularization procedures a proper glycemic control remains imperative.
再狭窄是指血管再通后管腔的再次变窄,这是临床实践中日益重要的问题。事实上,由于支架放置数量的增加,估计每年全世界超过 300 万例,血管再通术变得更加常见。一些研究人员已经证明,糖尿病患者的血管再狭窄风险增加。在这里,我们对糖尿病对支架内再狭窄的影响进行了系统的综述。目前讨论了再狭窄的分类和最新的流行病学,以及该事件病理生理学的主要机制。然后,我们总结了再狭窄的临床表现,强调了控制血糖在糖尿病患者中的重要性。事实上,在接受血管再通术的糖尿病患者中,适当的血糖控制仍然是必要的。
Cardiovasc Diabetol. 2022-2-14
Catheter Cardiovasc Interv. 2018-7
Rev Cardiovasc Med. 2024-12-24
Saudi J Med Med Sci. 2024
N Engl J Med. 2022-2-17
J Clin Invest. 2022-2-15
J Endovasc Ther. 2022-12
Diabetes Care. 2022-1-1